Heidelberg Pharma Publishes 2025 Financial Results and 2026 Outlook

Heidelberg Pharma AG reported its 2025 fiscal year financial results, highlighting significant developments. The year faced challenges, notably the delay in the approval for TLX250-Px, prompting Heidelberg Pharma to implement cost-cutting measures. The company's revenue in 2025 fell to EUR 6.9 million from EUR 12.0 million the previous year, with a net loss of EUR 42.3 million.

Dr. Dongzhou Jeffery Liu, the new CEO, emphasized the focus on advancing the Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101). Despite the financial setbacks, the company secured a USD 20 million payment from Soleus Capital, extending its cash runway to mid-2027. In 2026, the company anticipates generating sales revenue between EUR 11.0 million and EUR 15.0 million and is confident in its ATAC technology's potential in cancer treatment.